钆塞酸二钠给药后无肾源性系统性纤维化病例
该回顾性研究检索2008年7月至2019年12月全部钆塞酸二钠增强MRI检查,共7820次检查(5351例患者),其中299次检查eGFR为30-44 mL/min/1.73 m2、183次检查eGFR低于30 mL/min/1.73 m2。共识别18例活检确诊肾源性系统性纤维化患者,均未暴露于钆塞酸二钠;作者认为钆塞酸二钠在该人群中就肾源性系统性纤维化而言可能是安全的,但需进一步研究确认。
要点
- 共7820次钆塞酸二钠增强MRI检查,其中183次检查eGFR低于30 mL/min/1.73 m2、34次检查为血液透析患者。
- 18例活检确诊肾源性系统性纤维化患者均未暴露于钆塞酸二钠,未见给药后发生肾源性系统性纤维化的病例。
- 严重肾功能损伤患者钆塞酸二钠增强MRI检查的平均随访期为4.2年(范围0.2-11.3年)。
核心结论
- 作者认为,在该患者人群中钆塞酸二钠就肾源性系统性纤维化而言可能是安全的,但需进一步研究确认。
研究设计与样本
- 回顾性研究,通过电子病历检索2008年7月至2019年12月全部钆塞酸二钠增强MRI检查,共7820次检查、5351例患者(女性3022例、男性2329例)。
- 取每次检查前180天及以内的血清肌酐值计算eGFR,采用距每次MRI检查最近的eGFR值。
- 另行检索电子病历识别肾源性系统性纤维化患者,并对本机构皮肤科医生、肾内科医生进行调查以收集肾源性系统性纤维化病例。
诊断标准与关键数值
- eGFR 30-44 mL/min/1.73 m2者299次检查(242例患者),eGFR低于30 mL/min/1.73 m2者183次检查(157例患者)。
- eGFR 15-29 mL/min/1.73 m2者109次检查(94例患者),eGFR低于15 mL/min/1.73 m2者40次检查(39例患者),血液透析者34次检查(27例患者)。
- eGFR低于30 mL/min/1.73 m2或接受透析的17例患者接受钆塞酸二钠增强MRI两次或以上。
- 共识别18例活检确诊肾源性系统性纤维化患者,均未暴露于钆塞酸二钠。
临床应用与阅片要点
- 严重肾功能损伤患者接受钆塞酸二钠增强MRI检查后的平均随访期为4.2年(范围0.2-11.3年)。
- 作者认为钆塞酸二钠在该患者人群中就肾源性系统性纤维化而言可能是安全的,但需进一步研究确认。
局限性
- 作者指出需进一步研究确认该结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Gadoxetic acid (GA) has distinctive pharmacokinetic properties with important applications in hepatobiliary imaging. However, there are limited data evaluating the safety of GA administration in patients with impaired kidney function and the incidence of nephrogenic systemic fibrosis (NSF). Purpose To evaluate safety of GA regarding risk of NSF in patients with impaired kidney function. Materials and Methods This retrospective study identified all GA-enhanced MRI (hereafter, GA MRI) examinations performed between July 2008 and December 2019 through a search of the electronic medical record. Serum creatinine values within 180 days or less of each GA MRI examination were retrieved and estimated glomerular filtration rate (eGFR) was calculated. The eGFR value nearest to each MRI examination was used. A separate search in the electronic medical record was also performed to identify patients with NSF. Dermatologists, nephrologists, and nephrologists at our institution were surveyed for any cases of NSF. In patients with NSF, all MRI examinations performed and contrast agents administered to these patients were recorded. Results Overall, 7820 GA MRI examinations were identified, performed in 5351 patients (3022 women and 2329 men). These included 299 examinations (242 patients) with eGFR of 30-44 mL/min/1.73 m2 and 183 examinations (157 patients) with eGFR less than 30 mL/min/1.73 m2. There were 109 examinations (in 94 patients) with eGFR of 15-29 mL/min/1.73 m2, 40 examinations (in 39 patients) with eGFR less than 15 mL/min/1.73 m2, and 34 examinations in 27 patients undergoing hemodialysis. Seventeen patients with eGFR less than 30 mL/min/1.73 m2 or undergoing dialysis underwent GA MRI two or more times. Eighteen patients with biopsy-confirmed NSF were identified, none of whom were exposed to GA. The mean follow-up period for GA MRI examinations performed in patients with severe kidney impairment was 4.2 years (range, 0.2-11.3 years). Conclusion Gadoxetic acid may be safe with respect to nephrogenic systemic fibrosis in this patient population, although further studies are needed to confirm this. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Davenport and Shankar in this issue.
引用
- Starekova J, Bruce RJ, Sadowski EA, et al. No Cases of Nephrogenic Systemic Fibrosis after Administration of Gadoxetic Acid. Radiology. 2020. PMID: 32990511. doi:10.1148/radiol.2020200788
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。